A Phase 1 interventional study of LY900014 and Insulin Lispro in Type 1 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 2 sites in 2 countries. Open to participants aged 6 Years to 64 Years. Per ClinicalTrials.gov, last updated 2020-06-18.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 — 3 open to participants now, 3 under way, none of them phase 3. Insulin Lispro · Diabetes Mellitus, Type 1.
Among the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, this one is the 28th largest by enrollment, is one of 8 that started in 2018, is one of 22 in phase 1, and was the 45th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →3 of the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 are open now, in 3 countries. Recruiting first, the newest first:
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 7–18
Manchester University NHS Foundation Trust · Sites in United Kingdom
Ages 18–99
Tel-Aviv Sourasky Medical Center · Sites in Israel
Ages 18+
By country, each count listing its studies:
Insulin Lispro: first FDA approval 1996 (HUMALOG KWIKPEN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.
This study: 6 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 9 · Phase 3 14 · Phase 4 12
First in 2002; this study’s year is marked. 8 started in 2018.
This study's enrollment of 56 is above the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 38 across the 69 interventional studies. Of the 60 that completed or were terminated, 33 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 69 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company: 4 open now, 6 under way, 4 of them phase 3. Of 66 finished, 49 (74%) have results posted.
Among the 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company, this one is the 37th largest by enrollment of the 72 interventional ones that give a count, is one of 8 that started in 2018, is one of 33 in phase 1, and was the 47th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 1 studies by the year they started, since 2002.
1 of the studies testing Insulin Lispro in Diabetes Mellitus, Type 1 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06532461Steno Diabetes Center CopenhagenA Trial of Three- and Seven-days Insulin Infusions Set | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, from their registry updates:
Among Eli Lilly and Company’s 75 in Diabetes Mellitus, Type 1:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare LY900014 with insulin lispro (Humalog) in participants with type 1 diabetes mellitus.
There are 2 parts to this study. Part A is investigating how the body processes LY900014 and the effect of LY900014 on blood sugar levels compared to insulin lispro (Humalog) when study treatment is given by subcutaneous injection. Part B of the study is investigating how the body processes LY900014 and the effect of LY900014 on blood sugar levels compared to insulin lispro (Humalog) when study treatment is given by continuous subcutaneous insulin infusion (CSII) pump.
Screening is required within 28 days prior to the start of the study. For each participant, the study will last about 40 days in each part.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received single 0.2 U/kg of body weight subcutaneous (SC) bolus injection of 100 U/mL LY900014.
Drug: LY900014
Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL of Humalog.
Drug: Insulin Lispro
Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 delivered using the continuous subcutaneous insulin infusion (CSII) pump.
Drug: LY900014
Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL Humalog delivered using the CSII pump.
Drug: Insulin Lispro
Administered via SC injection
Also known as: Ultra-Rapid Lispro
Administered via SC injection
Also known as: Humalog, LY275585
Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC) Following Each Treatment Arm for Each Study Part
Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC(0 -7h)) following Each Treatment Arm for Each Study Part.
Time frame: Predose, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 90, 120, 150, 180, 240, 300, 360, and 420 minutes postdose
Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Versus Time Curve Following Each Treatment Arm for Each Study Part
Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Versus Time Curve (BG∆AUC(0-5h)) Following Each Treatment Arm for Each Study Part.
Time frame: -30, -15, 0 (predose), 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 135, 150, 165, 180, 195, 210, 225, 240 and 300 minutes postdose
Participants (pts) who completed Part A but discontinued before the beginning of Part B were replaced by newly enrolled participants in Part B.
| Milestone | Sequence 1-Part A | Sequence 2-Part A | Sequence 1-Part B | Sequence 2-Part B |
|---|---|---|---|---|
| Started | 21 | 21 | 0 | 0 |
| Received at least 1 dose of study drug | 21 | 21 | 0 | 0 |
| Children (2-11 years) | 7 | 6 | 0 | 0 |
| Adolescents (12-17 years) | 7 | 7 | 0 | 0 |
| Adults (18-64 years) | 7 | 8 | 0 | 0 |
| Completed | 21 | 20 | 0 | 0 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
| Milestone | Sequence 1-Part A | Sequence 2-Part A | Sequence 1-Part B | Sequence 2-Part B |
|---|---|---|---|---|
| Started | 21 | 20 | 0 | 0 |
| Children (2-11 years) | 7 | 6 | 0 | 0 |
| Adolescents (12-17 years) | 7 | 7 | 0 | 0 |
| Adults (18-64 years) | 7 | 7 | 0 | 0 |
| Completed | 21 | 20 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1-Part A | Sequence 2-Part A | Sequence 1-Part B | Sequence 2-Part B |
|---|---|---|---|---|
| Started | 0 | 0 | 20 | 19 |
| Received at least 1 dose of study drug | 0 | 0 | 20 | 17 |
| Children (2-11 years) | 0 | 0 | 6 | 6 |
| Adolescents (12-17 years) | 0 | 0 | 7 | 6 |
| Adults (18-64 years) | 0 | 0 | 7 | 5 |
| Completed | 0 | 0 | 20 | 17 |
| Not completed | 0 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 |
| Milestone | Sequence 1-Part A | Sequence 2-Part A | Sequence 1-Part B | Sequence 2-Part B |
|---|---|---|---|---|
| Started | 0 | 0 | 20 | 17 |
| Children (2-11 years) | 0 | 0 | 6 | 6 |
| Adolescents (12-17 years) | 0 | 0 | 7 | 6 |
| Adults (18-64 years) | 0 | 0 | 7 | 5 |
| Completed | 0 | 0 | 20 | 17 |
| Not completed | 0 | 0 | 0 | 0 |
Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC(0 -7h)) following Each Treatment Arm for Each Study Part.
| Picomoles*hour/Liter (pmol*h/L) | Children-LY900014-Part A | Children-Humalog-Part A | Adolescents-LY900014-Part A | Adolescents-Humalog-Part A | Adults-LY900014-Part A | Adults-Humalog-Part A | Children-LY900014-Part B | Children-Humalog-Part B | Adolescents-LY900014-Part B | Adolescents-Humalog-Part B | Adults-LY900014-Part B | Adults-Humalog-Part B |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC) Following Each Treatment Arm for Each Study Part | 755 ± 15 | 754 ± 17 | 962 ± 17 | 908 ± 21 | 987 ± 20 | 975 ± 21 | 743 ± 17 | 714 ± 17 | 842 ± 20 | 866 ± 16 | 1100 ± 35 | 1070 ± 35 |
Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Versus Time Curve (BG∆AUC(0-5h)) Following Each Treatment Arm for Each Study Part.
| milligrams*hour per deciliter (mg*h/dL) | Children-LY900014-Part A | Children-Humalog-Part A | Adolescents-LY900014-Part A | Adolescents-Humalog-Part A | Adults-LY900014-Part A | Adults-Humalog-Part A | Children-LY900014-Part B | Children-Humalog-Part B | Adolescents-LY900014-Part B | Adolescents-Humalog-Part B | Adults-LY900014-Part B | Adults-Humalog-Part B |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Versus Time Curve Following Each Treatment Arm for Each Study Part | 384 ± 335 | 492 ± 270 | 577 ± 247 | 651 ± 238 | 372 ± 179 | 351 ± 240 | 602 ± 221 | 582 ± 254 | 614 ± 160 | 614 ± 163 | 343 ± 194 | 401 ± 235 |
Collected over From Baseline to Study Completion (Up to 20 Months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Children-LY900014-Part A | 0/13 (0%) | 0/13 (0%) | 4/13 (30.8%) |
| Children-Humalog-Part A | 0/13 (0%) | 0/13 (0%) | 4/13 (30.8%) |
| Adolescents-LY900014-Part A | 0/14 (0%) | 1/14 (7.1%) | 6/14 (42.9%) |
| Adolescents-Humalog-Part A | 0/14 (0%) | 0/14 (0%) | 3/14 (21.4%) |
| Adults-LY900014-Part A | 0/14 (0%) | 0/14 (0%) | 2/14 (14.3%) |
| Adults-Humalog-Part A | 0/15 (0%) | 0/15 (0%) | 2/15 (13.3%) |
| Children-LY900014-Part B | 0/12 (0%) | 0/12 (0%) | 6/12 (50%) |
| Children-Humalog-Part B | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| Adolescents-LY900014-Part B | 0/13 (0%) | 0/13 (0%) | 3/13 (23.1%) |
| Adolescents-Humalog-Part B | 0/13 (0%) | 0/13 (0%) | 1/13 (7.7%) |
| Adults-LY900014-Part B | 0/12 (0%) | 0/12 (0%) | 3/12 (25%) |
| Adults-Humalog-Part B | 0/12 (0%) | 0/12 (0%) | 2/12 (16.7%) |
| Event | Children-LY900014-Part A | Children-Humalog-Part A | Adolescents-LY900014-Part A | Adolescents-Humalog-Part A | Adults-LY900014-Part A | Adults-Humalog-Part A | Children-LY900014-Part B | Children-Humalog-Part B | Adolescents-LY900014-Part B | Adolescents-Humalog-Part B | Adults-LY900014-Part B | Adults-Humalog-Part B |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| InjuryInjury, poisoning and procedural complications | 0/13 | 0/13 | 1/14 | 0/14 | 0/14 | 0/15 | 0/12 | 0/12 | 0/13 | 0/13 | 0/12 | 0/12 |
| Event | Children-LY900014-Part A | Children-Humalog-Part A | Adolescents-LY900014-Part A | Adolescents-Humalog-Part A | Adults-LY900014-Part A | Adults-Humalog-Part A | Children-LY900014-Part B | Children-Humalog-Part B | Adolescents-LY900014-Part B | Adolescents-Humalog-Part B | Adults-LY900014-Part B | Adults-Humalog-Part B |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Injection site erythemaGeneral disorders | 2/13 | 0/13 | 2/14 | 1/14 | 1/14 | 0/15 | 0/12 | 0/12 | 0/13 | 0/13 | 1/12 | 0/12 |
| NasopharyngitisInfections and infestations | 1/13 | 2/13 | 1/14 | 0/14 | 0/14 | 0/15 | 0/12 | 0/12 | 0/13 | 0/13 | 0/12 | 0/12 |
| Abdominal painGastrointestinal disorders | 0/13 | 0/13 | 0/14 | 0/14 | 0/14 | 0/15 | 1/12 | 1/12 | 0/13 | 0/13 | 0/12 | 0/12 |
| Feeling hotGeneral disorders | 0/13 | 0/13 | 0/14 | 0/14 | 0/14 | 0/15 | 1/12 | 0/12 | 0/13 | 0/13 | 0/12 | 0/12 |
| Injection site painGeneral disorders | 1/13 | 0/13 | 0/14 | 1/14 | 0/14 | 0/15 | 1/12 | 0/12 | 1/13 | 0/13 | 1/12 | 1/12 |
| Injection site pruritusGeneral disorders | 0/13 | 0/13 | 0/14 | 0/14 | 0/14 | 0/15 | 0/12 | 0/12 | 0/13 | 0/13 | 0/12 | 1/12 |
| CystitisInfections and infestations | 0/13 | 0/13 | 0/14 | 0/14 | 0/14 | 0/15 | 0/12 | 0/12 | 0/13 | 0/13 | 0/12 | 1/12 |
| Ear infectionInfections and infestations | 0/13 | 0/13 | 0/14 | 0/14 | 0/14 | 0/15 | 1/12 | 0/12 | 0/13 | 0/13 | 0/12 | 0/12 |
| GastroenteritisInfections and infestations | 0/13 | 0/13 | 0/14 | 0/14 | 0/14 | 0/15 | 0/12 | 1/12 | 0/13 | 0/13 | 0/12 | 0/12 |
| Upper respiratory tract infectionInfections and infestations | 0/13 | 0/13 | 0/14 | 0/14 | 0/14 | 0/15 | 1/12 | 1/12 | 0/13 | 0/13 | 0/12 | 0/12 |
All newly randomized participants of Part A and Part B.
| Age, Continuous(Years) | Part A | Part B | Total |
|---|---|---|---|
| Mean | 20.5 ± 15.1 | 23.2 ± 11.1 | 21.2 ± 14.2 |
| Age, Customized(Participants) | Part A | Part B | Total |
|---|---|---|---|
| Children (2-11 Years) | 13 | 3 | 16 |
| Adolescents (12-17 years) | 14 | 2 | 16 |
| Adults (18-64 years) | 15 | 9 | 24 |
| Sex: Female, Male(Participants) | Part A | Part B | Total |
|---|---|---|---|
| Female | 20 | 8 | 28 |
| Male | 22 | 6 | 28 |
| Ethnicity (NIH/OMB)(Participants) | Part A | Part B | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 2 |
| Not Hispanic or Latino | 40 | 14 | 54 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part A | Part B | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 37 | 11 | 48 |
| More than one race | 3 | 1 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Part A | Part B | Total |
|---|---|---|---|
| Canada | 28 | 10 | 38 |
| Germany | 14 | 4 | 18 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2018 to primary completion in Nov 2019, 19 months.
Results were first posted in Jun 2020, 7 months after primary completion.
Of 98 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 19 months is above that.
Counting every sponsor, half of 153 studies reached it within 12 months; a quarter within 5 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Lispro